keyword
https://read.qxmd.com/read/38487525/peritumoral-brain-zone-in-glioblastoma-biological-clinical-and-mechanical-features
#1
REVIEW
Alberto Ballestín, Daniele Armocida, Valentino Ribecco, Giorgio Seano
Glioblastoma is a highly aggressive and invasive tumor that affects the central nervous system (CNS). With a five-year survival rate of only 6.9% and a median survival time of eight months, it has the lowest survival rate among CNS tumors. Its treatment consists of surgical resection, subsequent fractionated radiotherapy and concomitant and adjuvant chemotherapy with temozolomide. Despite the implementation of clinical interventions, recurrence is a common occurrence, with over 80% of cases arising at the edge of the resection cavity a few months after treatment...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38487014/glioblastoma-stem-cell-derived-exosomal-mir-374b-3p-promotes-tumor-angiogenesis-and-progression-through-inducing-m2-macrophages-polarization
#2
JOURNAL ARTICLE
Shilu Huang, Peng Zhang, Nanheng Yin, Zhipeng Xu, Xinglei Liu, Anyi Wu, Xiaopei Zhang, Zengyang Li, Zhicheng Zhang, Tao Zhong, Liang Liu, Yan Shi, Jun Dong
Glioblastoma stem cells (GSCs) reside in hypoxic periarteriolar niches of glioblastoma micro-environment, however, the crosstalk of GSCs with macrophages on regulating tumor angiogenesis and progression are not fully elucidated. GSCs-derived exosomes (GSCs-exos) are essential mediators during tumor immune-microenvironment remodeling initiated by GSCs, resulting in M2 polarization of tumor-associated macrophages (TAMs) as we reported previously. Our data disclosed aberrant upregulation of miR-374b-3p in both clinical glioblastoma specimens and human cell lines of GSCs...
March 15, 2024: IScience
https://read.qxmd.com/read/38481999/systemic-and-local-immunosuppression-in-glioblastoma-and-its-prognostic-significance
#3
REVIEW
Aleksei A Stepanenko, Anastasiia O Sosnovtseva, Marat P Valikhov, Anastasia A Chernysheva, Olga V Abramova, Konstantin A Pavlov, Vladimir P Chekhonin
The effectiveness of tumor therapy, especially immunotherapy and oncolytic virotherapy, critically depends on the activity of the host immune cells. However, various local and systemic mechanisms of immunosuppression operate in cancer patients. Tumor-associated immunosuppression involves deregulation of many components of immunity, including a decrease in the number of T lymphocytes (lymphopenia), an increase in the levels or ratios of circulating and tumor-infiltrating immunosuppressive subsets [e.g., macrophages, microglia, myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs)], as well as defective functions of subsets of antigen-presenting, helper and effector immune cell due to altered expression of various soluble and membrane proteins (receptors, costimulatory molecules, and cytokines)...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38462406/creation-of-signatures-and-identification-of-molecular-subtypes-based-on-disulfidptosis-related-genes-for-glioblastoma-patients-prognosis-and-immunological-activity
#4
JOURNAL ARTICLE
Dongjun Li, Xiaodong Li, Jianfeng Lv, Shaoyi Li
BACKGROUND: In recent times, disulfidptosis, an intricate form of cellular demise, has garnered attention due to its impact on prognosis, tumor progression and treatment response. Nevertheless, the exact significance of disulfidptosis-related genes (DisRGs) in glioblastoma (GBM) remains enigmatic. METHODS: The GEO and TCGA databases provided transcriptional and clinically relevant data on tumor samples, while the GTEx database provided data on healthy tissues. Disulfidptosis-related genes (DisRGs) were procured from previous scholarly investigations...
March 9, 2024: Asian Journal of Surgery
https://read.qxmd.com/read/38449858/targeting-wnt-signaling-for-improved-glioma-immunotherapy
#5
JOURNAL ARTICLE
Margarita Gutova, Jonathan C Hibbard, Eric Ma, Heini M Natri, Vikram Adhikarla, Nyam-Osor Chimge, Runxiang Qiu, Cu Nguyen, Elizabeth Melendez, Brenda Aguilar, Renate Starr, Holly Yin, Russel C Rockne, Masaya Ono, Nicholas E Banovich, Yate-Ching Yuan, Christine E Brown, Michael Kahn
INTRODUCTION: Despite aggressive standard-of-care therapy, including surgery, radiation, and chemotherapy, glioblastoma recurrence is almost inevitable and uniformly lethal. Activation of glioma-intrinsic Wnt/β-catenin signaling is associated with a poor prognosis and the proliferation of glioma stem-like cells, leading to malignant transformation and tumor progression. Impressive results in a subset of cancers have been obtained using immunotherapies including anti-CTLA4, anti-PD-1, and anti-PD-L1 or chimeric antigen receptor (CAR) T cell therapies...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38418880/compartmentalized-ocular-lymphatic-system-mediates-eye-brain-immunity
#6
JOURNAL ARTICLE
Xiangyun Yin, Sophia Zhang, Ju Hyun Lee, Huiping Dong, George Mourgkos, Gordon Terwilliger, Aurora Kraus, Luiz Henrique Geraldo, Mathilde Poulet, Suzanne Fischer, Ting Zhou, Farrah Shalima Mohammed, Jiangbing Zhou, Yongfu Wang, Seth Malloy, Nicolas Rohner, Lokesh Sharma, Irene Salinas, Anne Eichmann, Jean-Leon Thomas, W Mark Saltzman, Anita Huttner, Caroline Zeiss, Aaron Ring, Akiko Iwasaki, Eric Song
The eye, an anatomical extension of the central nervous system (CNS), exhibits many molecular and cellular parallels to the brain. Emerging research demonstrates that changes in the brain are often reflected in the eye, particularly in the retina1 . Still, the possibility of an immunological nexus between the posterior eye and the rest of the CNS tissues remains unexplored. Here, studying immune responses to herpes simplex virus in the brain, we observed that intravitreal immunization protects mice against intracranial viral challenge...
February 28, 2024: Nature
https://read.qxmd.com/read/38411438/sexual-biased-necroinflammation-is-revealed-as-a-predictor-of-bevacizumab-benefit-in-glioblastoma
#7
JOURNAL ARTICLE
Sara Hiller-Vallina, Lucia Mondejar-Ruescas, Marta Caamaño-Moreno, Blanca Cómitre-Mariano, Denisse Alcivar-López, Juan M Sepulveda, Aurelio Hernández-Laín, Ángel Pérez-Núñez, Berta Segura-Collar, Ricardo Gargini
BACKGROUND: Glioblastoma (GBM) is a highly malignant brain tumor that affects men more often than women. In addition, the former shows a poorer survival prognosis. To date the reason for this sex-specific aggressiveness remains unclear. Therefore, the aim of this study is to investigate tumor processes that explain these sex differences. METHODS: This was a retrospective study of GBM patients which was stratified according to sex. Cohort with 73 tumors were analyzed with immunohistochemistry, RNA-seq and RT-qPCR to characterize differences in vascular and immunological profiles...
February 27, 2024: Neuro-oncology
https://read.qxmd.com/read/38404571/mgmt-unmethylation-and-high-levels-of-cd47-and-tigit-indicate-a-poor-prognosis-in-adult-diffuse-gliomas
#8
JOURNAL ARTICLE
Lingbo Ma, Yi Shi, Chang Li, Bin Deng, Jinfang Jiang, Yuwen Cao, Lianghai Wang, Hongyan Li
INTRODUCTION: In 2021, the World Health Organization published a new classification system for central nervous system tumors. This study reclassified the adult diffuse glioma (ADG) into astrocytoma, oligodendroglioma, and glioblastoma (GBM) according to the new tumor classification. METHODS: The association of TERT promoter (pTERT) mutation, MGMT methylation, and CD47/TIGIT expression with patient prognosis was investigated. RESULTS: Immunohistochemical analysis showed that the expression levels of CD47 and TIGIT in tumor tissues were significantly higher than those in normal brain tissues...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38390330/the-need-for-paradigm-shift-prognostic-significance-and-implications-of-standard-therapy-related-systemic-immunosuppression-in-glioblastoma-for-immunotherapy-and-oncolytic-virotherapy
#9
REVIEW
Aleksei A Stepanenko, Anastasiia O Sosnovtseva, Marat P Valikhov, Anastasia A Chernysheva, Olga V Abramova, Victor A Naumenko, Vladimir P Chekhonin
Despite significant advances in our knowledge regarding the genetics and molecular biology of gliomas over the past two decades and hundreds of clinical trials, no effective therapeutic approach has been identified for adult patients with newly diagnosed glioblastoma, and overall survival remains dismal. Great hopes are now placed on combination immunotherapy. In clinical trials, immunotherapeutics are generally tested after standard therapy (radiation, temozolomide, and steroid dexamethasone) or concurrently with temozolomide and/or steroids...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38389103/hypoxic-glioblastoma-cell-derived-extracellular-vesicles-impair-cgas-sting-activity-in-macrophages
#10
JOURNAL ARTICLE
Stoyan Tankov, Marija Petrovic, Marc Lecoultre, Felipe Espinoza, Nadia El-Harane, Viviane Bes, Sylvie Chliate, Darel Martinez Bedoya, Olivier Jordan, Gerrit Borchard, Denis Migliorini, Valérie Dutoit, Paul R Walker
BACKGROUND: Solid tumors such as glioblastoma (GBM) exhibit hypoxic zones that are associated with poor prognosis and immunosuppression through multiple cell intrinsic mechanisms. However, release of extracellular vesicles (EVs) has the potential to transmit molecular cargos between cells. If hypoxic cancer cells use EVs to suppress functions of macrophages under adequate oxygenation, this could be an important underlying mechanism contributing to the immunosuppressive and immunologically cold tumor microenvironment of tumors such as GBM...
February 22, 2024: Cell Communication and Signaling: CCS
https://read.qxmd.com/read/38384458/adoptive-cell-therapy-for-high-grade-gliomas-using-simultaneous-temozolomide-and-intracranial-mgmt-modified-%C3%AE-%C3%AE-t-cells-following-standard-post-resection-chemotherapy-and-radiotherapy-current-strategy-and-future-directions
#11
JOURNAL ARTICLE
L B Nabors, L S Lamb, T Goswami, K Rochlin, S L Youngblood
Cellular therapies, including chimeric antigen receptor T cell therapies (CAR-T), while generally successful in hematologic malignancies, face substantial challenges against solid tumors such as glioblastoma (GBM) due to rapid growth, antigen heterogeneity, and inadequate depth of response to cytoreductive and immune therapies, We have previously shown that GBM constitutively express stress associated NKG2D ligands (NKG2DL) recognized by gamma delta (γδ) T cells, a minor lymphocyte subset that innately recognize target molecules via the γδ T cell receptor (TCR), NKG2D, and multiple other mechanisms...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38384384/patient-derived-organoids-recapitulate-glioma-intrinsic-immune-program-and-progenitor-populations-of-glioblastoma
#12
JOURNAL ARTICLE
Fumihiro Watanabe, Ethan W Hollingsworth, Jenna M Bartley, Lauren Wisehart, Rahil Desai, Annalisa M Hartlaub, Mark E Hester, Paula Schiapparelli, Alfredo Quiñones-Hinojosa, Jaime Imitola
Glioblastoma multiforme (GBM) is a highly lethal human cancer thought to originate from a self-renewing and therapeutically-resistant population of glioblastoma stem cells (GSCs). The intrinsic mechanisms enacted by GSCs during 3D tumor formation, however, remain unclear, especially in the stages prior to angiogenic/immunological infiltration. In this study, we performed a deep characterization of the genetic, immune, and metabolic profiles of GBM organoids from several patient-derived GSCs (GBMO). Despite being devoid of immune cells, transcriptomic analysis across GBMO revealed a surprising immune-like molecular program, enriched in cytokine, antigen presentation and processing, T-cell receptor inhibitors, and interferon genes...
February 2024: PNAS Nexus
https://read.qxmd.com/read/38380331/understanding-the-glioblastoma-tumor-microenvironment-leveraging-the-extracellular-matrix-to-increase-immunotherapy-efficacy
#13
JOURNAL ARTICLE
Jimena Collado, Lauren Boland, Jared T Ahrendsen, Jason Miska, Catalina Lee-Chang
Glioblastoma (GBM) accounts for approximately half of all malignant brain tumors, and it remains lethal with a five-year survival of less than 10%. Despite the immense advancements in the field, it has managed to evade even the most promising therapeutics: immunotherapies. The main reason is the highly spatiotemporally heterogeneous and immunosuppressive GBM tumor microenvironment (TME). Accounting for this complex interplay of TME-driven immunosuppression is key to developing effective therapeutics. This review will explore the immunomodulatory role of the extracellular matrix (ECM) by establishing its contribution to the TME as a key mediator of immune responses in GBM...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38358885/radiotherapy-induces-persistent-innate-immune-reprogramming-of-microglia-into-a-primed-state
#14
JOURNAL ARTICLE
Daniëlle C Voshart, Takuya Oshima, Yuting Jiang, Gideon P van der Linden, Anna P Ainslie, Luiza Reali Nazario, Fleur van Buuren-Broek, Ayla C Scholma, Hilmar R J van Weering, Nieske Brouwer, Jeffrey Sewdihal, Uilke Brouwer, Rob P Coppes, Inge R Holtman, Bart J L Eggen, Susanne M Kooistra, Lara Barazzuol
Over half of patients with brain tumors experience debilitating and often progressive cognitive decline after radiotherapy treatment. Microglia, the resident macrophages in the brain, have been implicated in this decline. In response to various insults, microglia can develop innate immune memory (IIM), which can either enhance (priming or training) or repress (tolerance) the response to subsequent inflammatory challenges. Here, we investigate whether radiation affects the IIM of microglia by irradiating the brains of rats and later exposing them to a secondary inflammatory stimulus...
February 14, 2024: Cell Reports
https://read.qxmd.com/read/38358441/identification-of-a-new-hla-a-0201-restricted-cytotoxic-t-lymphocyte-epitope-from-tc2n
#15
JOURNAL ARTICLE
Zhao Yang, Hongchuan Zhang, Xiaohui Xia, Jiangwei Zhang
Identification of cytotoxic T lymphocyte (CTL) epitopes from tumor related antigens is a promising approach for malignant tumor immunotherapy. TC2N, a recently identified tumor associated antigen from human glioblastoma, is regarded as a promising target of tumor-specific immunotherapy. As one of the most widely used histocompatibility molecules in Chinese is HLA-A*0201, we were able to identify the TC2N peptides that are provided by this molecular type. A panel of antigenic peptides produced from TC2N were predicted by using a computer tool...
February 15, 2024: European Journal of Microbiology & Immunology
https://read.qxmd.com/read/38322570/pan-analysis-reveals-cacybp-to-be-a-novel-prognostic-and-predictive-marker-for-multiple-cancers
#16
JOURNAL ARTICLE
Baosen Mo, Bijun Luo, Yuesong Wu
OBJECTIVES: Cancer has emerged as a global issue in terms of public health care and treatment. The significance of calcyclin binding protein ( CACYBP ) in various neoplasms suggests that it may serve as a novel biomarker for numerous types of human tumors. METHODS: Our research investigated the differences in CACYBP expression between cancer tissues and normal tissues using a total of 18,787 samples from multiple centers. To explore the prognostic factor of CACYBP in cancers, we utilized Cox regression analysis and Kaplan-Meier curves...
2024: American Journal of Translational Research
https://read.qxmd.com/read/38321173/systematic-pan-cancer-analyses-of-the-potential-function-of-the-golgi-scaffold-protein-paqr3
#17
JOURNAL ARTICLE
Zhe-Nan Ling, Lian-Lian Hong, Jian Wu, Zhi-Qiang Ling
Progesterone and AdipoQ Receptor 3 (PAQR3) is a member of the AdipoQ receptor. Our previous studies have found that PAQR3 plays a role as a candidate inhibitor in cardiac adenocarcinoma, breast cancer, gastric cancer and colorectal cancer, but the systematic analysis of PAQR3 in tumors is currently lacking. The objective of this study was to investigate the prognostic and therapeutic value of PAQR3 in 31 tumors. Through the analysis of TCGA, UALCAN, GEO, GEPIA2, TIMER, Kaplan-Meier plotter, TISIDB and other databases, it was found that the expression level of PAQR3 changed significantly in different tumor types, and the expression level of Neuroblastoma was very high...
February 6, 2024: Scientific Reports
https://read.qxmd.com/read/38320994/redox-responsive-polymer-micelles-co-encapsulating-immune-checkpoint-inhibitors-and-chemotherapeutic-agents-for-glioblastoma-therapy
#18
JOURNAL ARTICLE
Zhiqi Zhang, Xiaoxuan Xu, Jiawei Du, Xin Chen, Yonger Xue, Jianqiong Zhang, Xue Yang, Xiaoyuan Chen, Jinbing Xie, Shenghong Ju
Immunotherapy with immune checkpoint blockade (ICB) for glioblastoma (GBM) is promising but its clinical efficacy is seriously challenged by the blood-tumor barrier (BTB) and immunosuppressive tumor microenvironment. Here, anti-programmed death-ligand 1 antibodies (aPD-L1) are loaded into a redox-responsive micelle and the ICB efficacy is further amplified by paclitaxel (PTX)-induced immunogenic cell death (ICD) via a co-encapsulation approach for the reinvigoration of local anti-GBM immune responses. Consequently, the micelles cross the BTB and are retained in the reductive tumor microenvironment without altering the bioactivity of aPD-L1...
February 6, 2024: Nature Communications
https://read.qxmd.com/read/38318180/the-immunological-landscape-of-peripheral-blood-in-glioblastoma-patients-and-immunological-consequences-of-age-and-dexamethasone-treatment
#19
JOURNAL ARTICLE
Sophie A Dusoswa, Jan Verhoeff, Saskia van Asten, Joyce Lübbers, Marlous van den Braber, Sophie Peters, Sanne Abeln, Matheus H W Crommentuijn, Pieter Wesseling, William Peter Vandertop, Jos W R Twisk, Thomas Würdinger, David Noske, Yvette van Kooyk, Juan J Garcia-Vallejo
BACKGROUND: Glioblastomas manipulate the immune system both locally and systemically, yet, glioblastoma-associated changes in peripheral blood immune composition are poorly studied. Age and dexamethasone administration in glioblastoma patients have been hypothesized to limit the effectiveness of immunotherapy, but their effects remain unclear. We compared peripheral blood immune composition in patients with different types of brain tumor to determine the influence of age, dexamethasone treatment, and tumor volume...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38303726/glioblastoma-extracellular-vesicles-modulate-immune-pd-l1-expression-in-accessory-macrophages-upon-radiotherapy
#20
JOURNAL ARTICLE
Markus W Schweiger, Zohreh Amoozgar, Pierre Repiton, Robert Morris, Semer Maksoud, Michael Hla, Eric Zaniewski, David P Noske, Wilhelm Haas, Koen Breyne, Bakhos A Tannous
Glioblastoma (GBM) is the most aggressive brain tumor, presenting major challenges due to limited treatment options. Standard care includes radiation therapy (RT) to curb tumor growth and alleviate symptoms, but its impact on GBM is limited. In this study, we investigated the effect of RT on immune suppression and whether extracellular vesicles (EVs) originating from GBM and taken up by the tumor microenvironment (TME) contribute to the induced therapeutic resistance. We observed that (1) ionizing radiation increases immune-suppressive markers on GBM cells, (2) macrophages exacerbate immune suppression in the TME by increasing PD-L1 in response to EVs derived from GBM cells which is further modulated by RT, and (3) RT increases CD206-positive macrophages which have the most potential in inducing a pro-oncogenic environment due to their increased uptake of tumor-derived EVs...
February 16, 2024: IScience
keyword
keyword
30051
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.